

## **HHS Public Access**

Author manuscript

Radiology. Author manuscript; available in PMC 2024 April 10.

Published in final edited form as:

Radiology. 2023 November; 309(2): e239028. doi:10.1148/radiol.239028.

## Erratum for: Quantitative CT evaluation of emphysema progression over 10 years in the COPDGene Study

David Baraghoshi, MSTAT<sup>1</sup>, Matthew Strand, PhD<sup>1</sup>, Stephen M Humphries, PhD<sup>2</sup>, Raúl San José Estépar, PhD<sup>3</sup>, Gonzalo Vegas Sanchez-Ferrero, PhD<sup>3</sup>, Jean-Paul Charbonnier, PhD<sup>4</sup>, Rudolfs Latisenko, MSc<sup>4</sup>, Edwin K Silverman, MD, PhD<sup>5</sup>, James D Crapo, MD<sup>6</sup>, David A Lynch, MB<sup>2</sup>

<sup>1</sup>Division of Biostatistics, Environment and Health, National Jewish Health, Denver, Colorado, United States

<sup>2</sup>Department of Radiology, National Jewish Health, Denver, Colorado, United States

<sup>3</sup>Applied Chest Imaging Laboratory, Brigham and Women's Hospital, Boston, Massachusetts, United States; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, United States.

<sup>4</sup>Thirona, Nijmegen, The Netherlands

<sup>5</sup>Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.

<sup>6</sup>Division of Pulmonary and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States

In Appendex S5, a reference to *Model 2* was changed to **the Base model**.

## **Funding:**

This work was supported by NHLBI U01 HL089897 and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee comprised of AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer and Sunovion.